鉅子生物(02367.HK)公佈中期業績 淨利潤同比增長20.6% 依然心懷理想邁步向前
格隆匯8月27日丨鉅子生物(02367.HK)公佈，截至2025年6月30日止六個月，公司實現了穩健的業績增長，收入達到人民幣31.1億元，同比增長22.5%；淨利潤達到人民幣11.8億元，同比增長20.6%。公司相信，短期影響終會過去，而公司的長期競爭力並未被磨滅，鉅子人依然會心懷理想，邁步向前。
收入增長的主要原因是報吿期內公司深耕線上和線下渠道、提高精細化運營能力，鞏固明星單品的增長以及迭代升級核心產品並加強品牌營銷，提升品牌影響力。
科學研究是公司的底色，也是公司行穩致遠的基礎。報吿期內，公司研發支出人民幣41百萬元，研發支出佔收入比例1.3%。截至報吿期末，公司擁有超過140項在研項目。截至報吿期末，公司已獲授權及申請中專利達到186項，其中報吿期內新增19項。
可復美焦點系列的明星單品焦點面霜延續上市以來的良好表現，持續實現人羣破圈和聲量提升，併為二梯隊的焦點水乳等產品逐步打開市場認知。可復美秩序系列和噸噸系列也在順利培育過程中。報吿期內，可復美品牌實現收入人民幣25.4億元，同比增長22.7%。
可麗金於報吿期內銷售收入為人民幣502.7百萬元，較2024年同期上升26.9%，佔報吿期內總收益的16.1%。該增長是由於(1)公司持續拓展線上渠道，進一步提升品牌知名度；(2)明星單品大膜王升級迭代成功，貢獻收入增量。
截至報吿期末，在線下渠道，公司的產品進入約1,700家公立醫院，約3,000傢俬立醫院和診所，超過13萬家連鎖藥房門店和約6,000家CS/KA門店。公司亦通過天貓、抖音、京東、小紅書、快手等線上電商平台和社交平台進行銷售和推廣宣傳。
展望2025年下半年，公司將繼續堅定初心，加強科學技術研究和產業化探索，不斷鞏固公司的技術領先地位；做好品牌宣傳建設和消費者溝通，持續樹立品牌形象，為長期發展打好基礎；將各渠道的運營做細做紮實，在變化中沉澱可持續、高質量的能力和組織。雄關漫道真如鐵，而今邁步從頭越，公司將持續迭代，持續前進。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
